Literature DB >> 16504592

Effectiveness and safety of methylphenidate in adult attention deficit hyperactivity disorder in patients with epilepsy: an open treatment trial.

C M van der Feltz-Cornelis1, A P Aldenkamp.   

Abstract

OBJECTIVE: The purpose of this study was to evaluate the effectiveness and safety of methylphenidate treatment in epilepsy patients with comorbid adult attention deficit hyperactivity disorder (ADHD).
METHODS: Six of 156 consecutive patients attending a tertiary epilepsy clinic for diagnostic evaluation of new seizures, 3 patients with epilepsy and 3 patients with psychogenic non-epileptic seizures, were diagnosed with comorbid adult ADHD. These 6 patients entered an open trial of methylphenidate 10 mg twice daily. Clinical improvement was assessed at 6 weeks of follow-up.
RESULTS: Both groups showed clinical improvement of ADHD symptoms during treatment. None of the patients with comorbid epilepsy experienced adverse effects on seizure control or antiepileptic drug use.
CONCLUSION: In this open trial methylphenidate was safely used in patients with epilepsy and adult ADHD. It was effective against adult ADHD, and there were no adverse effects on seizure severity and frequency. A randomized study is needed to further establish effectiveness and safety.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16504592     DOI: 10.1016/j.yebeh.2006.01.015

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  9 in total

Review 1.  Stimulant and non-stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy.

Authors:  Chris Eaton; Kenneith Yong; Victoria Walter; Gashirai K Mbizvo; Sinead Rhodes; Richard Fm Chin
Journal:  Cochrane Database Syst Rev       Date:  2022-07-13

2.  Medication treatment for attention-deficit/hyperactivity disorder and the risk of acute seizures in individuals with epilepsy.

Authors:  Isabell Brikell; Qi Chen; Ralf Kuja-Halkola; Brian M D'Onofrio; Kelsey K Wiggs; Paul Lichtenstein; Catarina Almqvist; Patrick D Quinn; Zheng Chang; Henrik Larsson
Journal:  Epilepsia       Date:  2019-01-25       Impact factor: 5.864

Review 3.  The diagnosis and treatment of attention deficit hyperactivity disorder in patients with epilepsy.

Authors:  Mesha-Gay Brown; Danielle A Becker; John R Pollard; Christopher Todd Anderson
Journal:  Curr Neurol Neurosci Rep       Date:  2013-06       Impact factor: 5.081

4.  Methylphenidate, cognition, and epilepsy: A double-blind, placebo-controlled, single-dose study.

Authors:  Jesse Adams; Valerie Alipio-Jocson; Katherine Inoyama; Victoria Bartlett; Saira Sandhu; Jemima Oso; John J Barry; David W Loring; Kimford Meador
Journal:  Neurology       Date:  2016-12-28       Impact factor: 9.910

Review 5.  Epilepsy and attention-deficit hyperactivity disorder: links, risks, and challenges.

Authors:  Amy E Williams; Julianne M Giust; William G Kronenberger; David W Dunn
Journal:  Neuropsychiatr Dis Treat       Date:  2016-02-09       Impact factor: 2.570

6.  Adult ADHD and Comorbid Somatic Disease: A Systematic Literature Review.

Authors:  Johanne Telnes Instanes; Kari Klungsøyr; Anne Halmøy; Ole Bernt Fasmer; Jan Haavik
Journal:  J Atten Disord       Date:  2016-09-01       Impact factor: 3.256

Review 7.  Treating attention-deficit/hyperactivity disorder beyond symptom control alone in children and adolescents: a review of the potential benefits of long-acting stimulants.

Authors:  Jan Buitelaar; Rossella Medori
Journal:  Eur Child Adolesc Psychiatry       Date:  2009-10-13       Impact factor: 4.785

8.  Attention-deficit/hyperactivity disorder medication and seizures.

Authors:  Kelsey K Wiggs; Zheng Chang; Patrick D Quinn; Kwan Hur; Robert Gibbons; David Dunn; Isabell Brikell; Henrik Larsson; Brian M D'Onofrio
Journal:  Neurology       Date:  2018-02-23       Impact factor: 9.910

Review 9.  Methylphenidate for attention problems in epilepsy patients: Safety and efficacy.

Authors:  Beth A Leeman-Markowski; Jesse Adams; Samantha P Martin; Orrin Devinsky; Kimford J Meador
Journal:  Epilepsy Behav       Date:  2020-12-24       Impact factor: 2.937

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.